{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-22-000084","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.832001+00:00","generated_at":"2026-06-24T02:10:21.932424+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gossamer Bio Q2 net loss $56.5M; seralutinib Phase 2 readout on track for Nov/Dec 2022","bullets":["Net loss of $56.5M ($0.74/share) vs $59.8M ($0.80/share) in Q2 2021.","Cash, equivalents & marketable securities $222.2M as of June 30; pro forma $342M after $120M July 2022 private placement.","Seralutinib Phase 2 TORREY topline data expected second half November or first half December 2022.","GB5121 Phase 1b/2 STAR CNS study in PCNSL dosed first patient.","Commencing investment in registrational Phase 3 program for seralutinib targeted for Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-22-000084","json":"https://secwatch.observer/filing/0001728117-22-000084.json","markdown":"https://secwatch.observer/filing/0001728117-22-000084.md","text":"https://secwatch.observer/filing/0001728117-22-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000084/0001728117-22-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000084/goss-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:10:21.932424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}